DAA Letter on Questions from the National Clinical Care Commission

To: Linda Harris, Designated Federal Officer, National Clinical Care Commission 

"The DAA urges regulatory reforms that would allow CMS flexibility to cover innovative diabetes technologies and services, so that as new diabetes technologies and services are approved by the FDA, there is a coverage pathway in Medicare for them. Rapid advances in this space have outpaced Medicare’s existing coverage and reimbursement guidelines resulting in overly complicated or even a lack of, access processes for patients, health care professionals and suppliers."

Read the Full Letter